Welcome to our dedicated page for Mineralys Therapeutics news (Ticker: MLYS), a resource for investors and traders seeking the latest updates and insights on Mineralys Therapeutics stock.
Mineralys Therapeutics, Inc. develops medicines for hypertension and related comorbidities driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor being developed for hypertension, chronic kidney disease, obstructive sleep apnea and other aldosterone-related conditions.
Mineralys news commonly covers lorundrostat clinical data, FDA regulatory updates, New Drug Application developments, and corporate updates tied to clinical and regulatory funding. Other recurring announcements include quarterly financial results, health care conference participation, executive appointments, and employee equity inducement awards under Nasdaq Listing Rule 5635(c)(4).
Mineralys Therapeutics (Nasdaq: MLYS) reported that on August 10, 2026, a majority of its independent directors granted inducement equity awards to newly appointed Chief Medical Officer Dr. Terry Ferguson under the 2025 Employment Inducement Incentive Award Plan.
The grant includes a stock option for 135,000 shares of common stock and a restricted stock unit (RSU) award for 102,400 shares. The option vests over four years, with 25% vesting on the first anniversary of the vesting commencement date, August 10, 2026, and the remainder vesting in equal monthly installments over the following three years, subject to continued service. The RSUs vest in four equal annual installments over four years starting August 10, 2026, also subject to continued service. According to Mineralys, these awards were granted as an inducement material to Dr. Ferguson’s employment, in line with Nasdaq Listing Rule 5635(c)(4).
Mineralys Therapeutics (Nasdaq: MLYS) reported second quarter 2026 results and progress on lorundrostat, its aldosterone synthase inhibitor for hypertension. The FDA is reviewing the lorundrostat NDA with a PDUFA target date of December 22, 2026, and the company is advancing commercial launch preparations.
Mineralys appointed cardiovascular specialist James J. “Terry” Ferguson III, M.D. as Chief Medical Officer, effective August 10, 2026, while former CMO David Rodman becomes a full-time Strategic Advisor. The company strengthened lorundrostat economics by amending its Tanabe license, eliminating royalties in exchange for a $200 million upfront payment and up to $255 million in commercial milestones plus up to $10 million tied to a potential second indication.
Second quarter 2026 cash, cash equivalents and investments totaled $661.4 million, and Mineralys believes this will fund planned operations, including a potential launch, into 2028. Quarterly R&D expenses rose to $221.4 million, largely due to the Tanabe payment, G&A expenses were $24.7 million, and net loss was $241.1 million or $(2.85) per share.
Mineralys Therapeutics (Nasdaq: MLYS) will report its financial results for the second quarter ended June 30, 2026, after market close on Tuesday, August 11, 2026. The company will host a conference call and live webcast at 4:30 p.m. ET for investors and analysts.
Mineralys Therapeutics (Nasdaq: MLYS) reported equity inducement awards granted under its 2025 Employment Inducement Incentive Award Plan to new non-executive employees, in line with Nasdaq Listing Rule 5635(c)(4). On July 17 and July 20, 2026, the Compensation Committee approved stock options over a total of 42,800 shares and restricted stock unit (RSU) awards over 32,100 shares of common stock. The options vest monthly over four years after a one-year cliff, while the RSUs vest in four equal annual installments from vesting commencement dates of July 13 and July 20, 2026, contingent on continued service.
Mineralys Therapeutics (Nasdaq: MLYS) presented late-breaking data at ENDO 2026 on lorundrostat’s effects on heart failure (HF) risk biomarkers in uncontrolled hypertension. A post hoc proteomic analysis of 1,004 participants from the Launch-HTN and Advance-HTN trials showed significant changes in RAAS-related and HF risk biomarkers.
Lorundrostat was associated with increased renin, decreased angiotensinogen, and reductions in 6 of 11 candidate causal HF biomarkers, including NT-proBNP. Coordinated shifts in fibrosis, hemostasis and protease inhibitor markers support further evaluation of lorundrostat’s therapeutic potential in HF. Lorundrostat is under FDA review with a PDUFA target date of December 22, 2026.
Mineralys Therapeutics (NASDAQ: MLYS) announced participation in the Goldman Sachs 47th Annual Global Healthcare Conference in Miami, held June 8-10, 2026.
Management will join a fireside chat on Tuesday, June 9, 2026, at 2:40 p.m. ET, with a live webcast available via the company’s investor relations website.
Mineralys Therapeutics (Nasdaq: MLYS) will present late-breaking data on lorundrostat at ENDO 2026. The poster covers a post hoc proteomic analysis of heart failure risk biomarkers in participants with uncontrolled hypertension from the Launch-HTN and Advance-HTN trials, on June 14, 2026, in Chicago.
Mineralys Therapeutics (Nasdaq: MLYS) priced an underwritten public offering of 5,660,378 shares of common stock at $26.50 per share, for expected gross proceeds of about $150 million before expenses.
Net proceeds will help fund a $200 million upfront payment to repurchase a royalty obligation under a Tanabe Pharma license. The offering should close on or about June 4, 2026, subject to customary conditions. Earlier the company entered into a $500 million committed debt facility with funds managed by Pharmakon Advisors.
Mineralys Therapeutics (NASDAQ: MLYS) will repurchase all future lorundrostat royalties owed to Tanabe for $200 million upfront plus up to $100 million in commercial milestone payments. Aggregate remaining milestone obligations total up to $265 million. Tanabe will also assign lorundrostat IP rights to Mineralys.
The company entered a $500 million senior secured term loan with Pharmakon, with $100 million funded at closing, maturing in June 2031 at SOFR (3.25% floor) + 5.50%. Mineralys also priced an underwritten $150 million common stock offering.
Mineralys Therapeutics (Nasdaq: MLYS) reported new Phase 3 Launch-HTN data on lorundrostat in participants with hypertension and chronic kidney disease (CKD). Once-daily 50 mg lorundrostat produced significant placebo-adjusted systolic blood pressure reductions at 12 weeks and a 52.2% urinary albumin-to-creatinine ratio decrease in CKD patients with baseline albuminuria, with a favorable safety profile. Lorundrostat is under FDA review with a PDUFA target date of December 22, 2026.